Wegovy FDA Approval: CV Risk and Weight Management in Obesity

Overview Wegovy (semaglutide) is a long‑acting GLP‑1 receptor agonist available as a once‑weekly subcutaneous injection and a once‑daily high‑dose oral tablet. It is approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight,…






![Top 7 Wet Cough Syrups in India 2026 [Expectorants & Mucolytics Reviewed] Top 7 Wet Cough Syrups in India 2026](https://laafon.com/wp-content/uploads/2025/12/wet-cough-syrup-768x431.jpg)


